Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
Rhea-AI Summary
Biotricity (OTCQB:BTCY) reported Q3 fiscal 2026 results for the quarter ended December 31, 2025, showing continued revenue momentum and margin expansion.
Key metrics: revenue $4.0M (+10.2% YoY), gross margin 81.5%, recurring Technology Fees $3.6M (91.2% of revenue), and a reduced net loss of $1.1M.
Positive
- Revenue +10.2% to $4.0M in Q3-FY26
- Gross margin expanded to 81.5% (from 76.4%)
- Recurring Technology Fees of $3.6M comprised 91.2% of revenue
- Third consecutive quarter of positive EBITDA and net operating income
Negative
- Net loss remained $1.1M for Q3-FY26 despite improvement
News Market Reaction – BTCY
On the day this news was published, BTCY declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BTCY fell 4.64%, while several medical device peers also declined (e.g., CSDX -2.72%, GTHP -2.5%, PYNKF -1.02%). BTCY’s drop is steeper, suggesting a more stock-specific reaction despite some sector softness.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings call notice | Positive | +10.7% | Announcement of Q3 FY26 results call and positive EBITDA update. |
| Nov 14 | Earnings results | Positive | -9.1% | Q2 FY26 revenue growth, high gross margin, and narrower net loss. |
| Nov 07 | Earnings call notice | Neutral | -3.4% | Scheduling details for the upcoming Q2 FY26 results call. |
| Sep 09 | Commercial partnership | Positive | -14.1% | Collaboration to offer Bioheart to ~70M FSA and HSA users. |
| Sep 03 | Platform expansion | Positive | +15.7% | Expansion of cardiac monitoring platform to integrate consumer wearables. |
Operational and partnership news have produced mixed reactions, with both sharp gains and selloffs following positive updates, indicating inconsistent market response to BTCY’s growth narrative.
Over the last six months, BTCY has repeatedly highlighted revenue growth, margin expansion, and progress toward scalable profitability, including Q2 FY26 results on Nov 14, 2025 and today’s Q3 FY26 update. The company also advanced strategic collaborations and platform expansions, such as the B-Secur wearable integration and the Health-E Commerce Bioheart partnership. An earlier FY26 Q3 call announcement on Feb 05, 2026 was associated with a double‑digit gain, underscoring sensitivity to earnings-related communication.
Market Pulse Summary
This announcement highlights continued revenue growth to $4 million, an improved gross margin of 81.5%, and a narrower net loss of $1.1 million in Q3 FY26, with recurring technology fees comprising 91.2% of revenue. Recent history shows similar themes of margin expansion and scalability efforts. Investors may watch future filings and conference calls for updates on profitability sustainability, international expansion, and progress toward FDA clearance for the AI clinical model.
Key Terms
ebitda financial
fda clearance regulatory
form 10-k regulatory
AI-generated analysis. Not financial advice.
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.
Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “The need for proactive chronic care management has never been greater. We’re proud to deliver our third consecutive quarter of positive EBITDA and net operating income, which reflects continued revenue growth, sustained margins, and disciplined operational execution. Over the next 30 years, cardiovascular disease is projected to impact over
Biotricity is helping lead that transition by bringing clinical-grade, easy-to-use diagnostic solutions out of episodic care settings and into everyday life, where most meaningful health events occur. Our approach allows providers to extend care beyond traditional touchpoints so they can serve more patients and improve outcomes without adding additional workload. The strength of this model is reflected in our rapidly expanding digital ecosystem and high customer retention of 90+%. In just 2 years our app base has scaled from 4,500 to more than 44,000 users, and our network of over 2,500 providers that support 4,000,000 patients annually continues to grow.
Importantly, we’re on track to obtain FDA clearance for our groundbreaking AI clinical model in the coming months. Our Cardiac AI Cloud platform leverages more than two trillion anonymized heartbeats to enhance diagnostic accuracy, improving throughput. Combined with our automation and operational AI capabilities, our technologies enable us to scale efficiently and pass those efficiencies on to our customers. The result is higher-quality care, more patients served, and increased revenue opportunities for medical facilities, creating meaningful value across the care continuum with both providers and patients winning. By facilitating this, Biotricity is positioned for sustainable, long-term growth as customer satisfaction drives adoption and expansion, allowing us to continue to revolutionize the cardiac care landscape.”
Q3-FY26 Financial Highlights
- Revenue increased
10.2% to$4 million from$3.6 million in the corresponding prior year period - Gross margin was
81.5% for the three months ended December 31, 2025, as compared to76.4% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. - Net loss decreased to
$1.1 million , or$0.042 per share, from a net loss of$1.3 million , or$0.054 per share; this was a13% improvement from the corresponding prior year quarter.
Operating Highlights for Q3-FY26 and the Future
- Q3-FY26 recurring (TaaS) Technology Fees rose a robust
7.4% from the corresponding prior year period to$3.6 million , representing91.2% of total revenue for Q3-FY26 - The Company maintained its track record of strong customer retention, supported by the quality of its solutions, best-in-class customer support, and accuracy and ease-of-use of its diagnostic technology.
- With approvals in Canada, Saudi Arabia, and Argentina, the Company continued to advance strategic regulatory approvals across international markets, laying the foundation for distribution partnerships.
- Leveraging its seasoned sales force and strategic partnerships, the Company continued to expand its footprint across broader national markets, with penetration across thousands of cardiologists in hundreds of centers.
Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting www.sec.gov.
Financial Results and Business Update Conference Call
Management will host a conference call on Wednesday, February 11th, 2026 at 4:30 p.m. ET to discuss its financial results for fiscal third quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/
Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday February 11th, 2026
Time: 4:30pm ET (1:30pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday February 25, 2026 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
To learn more about the benefits of using Biotricity’s solutions, click here and here. For consumers interested in continuous, 24/7 clinical-grade monitoring at home with Bioheart, click here.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of any of the Company's products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
Media
Website
Facebook
Instagram
LinkedIn
YouTube
FAQ
What were Biotricity (BTCY) Q3-FY26 revenue and growth figures?
How did Biotricity (BTCY) margins and profitability change in Q3-FY26?
What is Biotricity's recurring revenue mix in Q3-FY26 for BTCY?
Did Biotricity (BTCY) report positive EBITDA in Q3-FY26?
What did Biotricity (BTCY) report about net loss and future catalysts?
